S. Diede

发表

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

James R. Anderson, R. Dummer, J. Larkin, 2019, The Lancet. Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas

Zizhen Yao, S. Tapscott, S. Diede, 2012, Epigenetics.

Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma

Jiali Han, Robert McDougall Kerr, I. Shui, 2022, Frontiers in Oncology.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

S. Groshen, K. Matthay, D. Haas-Kogan, 2018, Pediatric blood & cancer.

All things must end: telomere dynamics in yeast.

D. Gottschling, S. Diede, M. Dubois, 2000, Cold Spring Harbor symposia on quantitative biology.

A. Shillington, Frank X Liu, R. Joseph, 2020, Quality of Life Research.

Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta.

D. Gottschling, S. Diede, 1999, Cell.

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

TERT hypermethylation: biomarker in paediatric brain tumours.

S. Diede, 2013, The Lancet. Oncology.

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

A. Jenkner, K. Norga, Martha Donoghue, 2020, European journal of cancer.

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.

B. Geoerger, A. Pappo, A. Petrilli, 2019, The Lancet. Oncology.

Real-world experience with pembrolizumab in patients with advanced melanoma

Frank X Liu, S. Diede, E. Whitman, 2019, Medicine.

Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles

S. Tapscott, Hisashi Tanaka, Xiongfong Chen, 2013, Nucleic acids research.

The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku

D. Gottschling, S. Peterson, S. Diede, 2001, Nature Genetics.

Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart.

S. Tapscott, Hisashi Tanaka, A. Giuliano, 2017, Cell reports.

Expression of neurotrophins and the low-affinity NGF receptor in septal and hippocampal reaggregate cultures: local physiologic effects of NGF synthesized in the septal region.

B. Wainer, T. Large, U. Otten, 1992, Brain research. Developmental brain research.

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials

Meihua Wang, Chen Hu, Cong Chen, 2021, JAMA network open.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

R. Dummer, J. Wolchok, A. Ribas, 2020, European journal of cancer.

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

P. Ascierto, A. Ribas, H. Schmidt, 2020, Journal for ImmunoTherapy of Cancer.

Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere

D. Gottschling, S. Diede, Daniel E Gottschling, 2001, Current Biology.

Reduced Dosage of pos-1 Suppresses Mex Mutants and Reveals Complex Interactions Among CCCH Zinc-Finger Proteins During Caenorhabditis elegans Embryogenesis

S. Diede, Jennifer R. Tenlen, J. A. Schisa, 2006, Genetics.

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)☆☆☆☆☆☆

Yanhong Gu, H. Pan, Y. Shu, 2019, Translational oncology.

Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers

A. Shillington, Frank X Liu, R. Joseph, 2019, Journal of medical economics.

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.

A. Abernethy, Frank X Liu, A. Haiderali, 2019, Future oncology.

429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

R. Dummer, A. Ribas, Douglas B. Johnson, 2020, Journal for ImmunoTherapy of Cancer.

Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer

Zizhen Yao, J. Olson, S. Tapscott, 2013, Epigenetics.

Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Michael E. Lassman, J. Malvehy, R. Dummer, 2018 .

Real-world experience of pembrolizumab in patients with advanced melanoma: A large retrospective observational study.

S. Diede, E. Whitman, W. Ou, 2018, Annals of Oncology.

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.

B. Geoerger, A. Pappo, A. Petrilli, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .